In a recent response to a report prepared by Paul Hunt, former UN Special Rapporteur, the pharmaceutical company GlaxoSmithKline (GSK) has argued that the responsibilities of pharmaceutical companies with respect to the “right to health” is not clearly defined. GSK further comments that its current initiatives, such research and development programmes which target diseases of the developing world, and preferential pricing for low-income countries, do not constitute commitments required by international legal norms. GSK’s response is accessible here. Paul Hunt’s report can be downloaded at http://www.reports-and-materials.org/Paul-Hunt-report-on-GSK-5-May-2009.pdf.
- Book Review: ‘Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare’ by Peter Gøtzsche
- Forced to Flee: Humanitarian Disasters Leave Women at Higher Risk
- Looking for $2 Trillion
- Is Viral Load Testing for HIV a Realistic Strategy in Developing Countries?
- Vaccine Hesitancy: A Call for Papers from PLOS Currents: Outbreaks
- Drugs for the Poor, Drugs for the Rich: Why the Current R&D Model Doesn’t Deliver
TopicsAfrica antimicrobial drugs antiretroviral treatment cardiovascular health child health china clinical trials developing world diarrhea environment Ghostwriting global burden of disease global health guidelines health costs health information health policy health systems HIV HIV/AIDS influenza LMICs malaria maternal and perinatal health maternal health medical literature medical students Mental Health mortality MSF neglected tropical diseases open access pharmaceutical industry Policy public health reporting research ethics sanitation sub-saharan Africa systematic reviews tobacco tuberculosis vaccine water WHO